Overview

Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 Diabetes

Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the long term safety and effectiveness of three doses of vildagliptin, an unapproved drug, compared to placebo in lowering overall blood glucose levels in people with type 2 diabetes who have not previously been treated with drug therapy to lower their blood sugar.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Vildagliptin